Synthetic factor VIIa concentrate to treat coagulopathy and gastrointestinal bleeding in an infant with end-stage liver disease

Clinical Pediatrics

Volumn 41, Issue 8, 2002, Pages 613-616

  Tobias, Joseph D ^a   Berkenbosch, John W ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CASE REPORT; CHOLESTASIS; CLINICAL FEATURE; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE COURSE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFANT; LIVER DYSFUNCTION; LIVER FAILURE; MALE; TREATMENT PLANNING;

EID: 0036798887     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280204100810     Document Type: Article

References (15)

1. Lam J, Tobias JD. Initial experience with octreotide in the pediatric population. Am J Therapeutics. 2002;8:409-415.
2. Van't Veer C, Mann KG. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. Semin Thromb Hemostas. 2000;26:367-372.
3. Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemostas. 2000;26:363-366.
4. Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood. 1983;62:1135-1138.
5. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 1991;28:3-5.
6. Hedner U, Schulman S, Alberta KA, et al. Successful use of rFVIIa in a patient with severe hemophilia A subjected to synovectomy. Lancet. 1988;342(ii):1193.
7. White B, McHale J, Ravi N, et al. Successful use of recombinant factor VIIa (Novoseven) in the management of intractable post-surgical intra-abdominal hemorrhage. Br J Haematol. 1999;107:677-678.
8. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113;1930-1937.
9. Jeffers L, Bernstein DE, Erhardtsen E, et al. The use of recombinant factor VIIa in laparoscopy liver biopsy: a pilot trial (abstract). Gastroenterology. 1998;114:L0275.
10. Erhardtsen R, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrin. 1998;9:741-748.
11. Hendriks HGD, Meiher K, De Wolf JTM, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation. 2001;71:402-405.
12. Kalicinski P, Kaminski A, Drewniak H, et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Trans Proc. 1999;31:378-379.
13. Chuansumrit A, Treepongkaruna S, Phuapradit P, et al. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver disease. Thromb Haemost. 2001;85:748-749.
14. Poon MC, Demers C, Jobin F, Wu JWY. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999;94:3951-3953.
15. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26(suppl 1):159-164.